These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36462771)

  • 21. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading.
    Spatz JM; Ellman R; Cloutier AM; Louis L; van Vliet M; Suva LJ; Dwyer D; Stolina M; Ke HZ; Bouxsein ML
    J Bone Miner Res; 2013 Apr; 28(4):865-74. PubMed ID: 23109229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of sclerostin deletion in bisphosphonate-induced osteonecrosis of the jaw.
    Nakashima F; Matsuda S; Ninomiya Y; Ueda T; Yasuda K; Hatano S; Shimada S; Furutama D; Memida T; Kajiya M; Shukunami C; Ouhara K; Mizuno N
    Bone; 2024 Oct; 187():117200. PubMed ID: 39019131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conditional disruption of Pkd1 in osteoblasts results in osteopenia due to direct impairment of bone formation.
    Xiao Z; Zhang S; Cao L; Qiu N; David V; Quarles LD
    J Biol Chem; 2010 Jan; 285(2):1177-87. PubMed ID: 19887454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterozygous deletion of both sclerostin (Sost) and connexin43 (Gja1) genes in mice is not sufficient to impair cortical bone modeling.
    Grimston SK; Fontana F; Watkins M; Civitelli R
    PLoS One; 2017; 12(11):e0187980. PubMed ID: 29149200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postnatal Skeletal Deletion of Dickkopf-1 Increases Bone Formation and Bone Volume in Male and Female Mice, Despite Increased Sclerostin Expression.
    Colditz J; Thiele S; Baschant U; Niehrs C; Bonewald LF; Hofbauer LC; Rauner M
    J Bone Miner Res; 2018 Sep; 33(9):1698-1707. PubMed ID: 29734465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.
    Tu X; Rhee Y; Condon KW; Bivi N; Allen MR; Dwyer D; Stolina M; Turner CH; Robling AG; Plotkin LI; Bellido T
    Bone; 2012 Jan; 50(1):209-17. PubMed ID: 22075208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sostdc1 Suppression in the Absence of Sclerostin Potentiates Anabolic Action of Cortical Bone in Mice.
    Choi RB; Hoggatt AM; Horan DJ; Rogers EZ; Loots GG; Robling AG
    J Bone Miner Res; 2023 May; 38(5):765-774. PubMed ID: 36891756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity.
    Bonnet N; Standley KN; Bianchi EN; Stadelmann V; Foti M; Conway SJ; Ferrari SL
    J Biol Chem; 2009 Dec; 284(51):35939-50. PubMed ID: 19837663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.
    Sato AY; Cregor M; Delgado-Calle J; Condon KW; Allen MR; Peacock M; Plotkin LI; Bellido T
    J Bone Miner Res; 2016 Oct; 31(10):1791-1802. PubMed ID: 27163932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endochondral fracture healing with external fixation in the Sost knockout mouse results in earlier fibrocartilage callus removal and increased bone volume fraction and strength.
    Morse A; Yu NY; Peacock L; Mikulec K; Kramer I; Kneissel M; McDonald MM; Little DG
    Bone; 2015 Feb; 71():155-63. PubMed ID: 25445453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of sclerostin adversely affects B-cell survival.
    Cain CJ; Rueda R; McLelland B; Collette NM; Loots GG; Manilay JO
    J Bone Miner Res; 2012 Jul; 27(7):1451-61. PubMed ID: 22434688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
    Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sclerostin ablation prevents aortic valve stenosis in mice.
    Joll JE; Riley LA; Bersi MR; Nyman JS; Merryman WD
    Am J Physiol Heart Circ Physiol; 2022 Nov; 323(5):H1037-H1047. PubMed ID: 36240434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted deletion of Sost distal enhancer increases bone formation and bone mass.
    Collette NM; Genetos DC; Economides AN; Xie L; Shahnazari M; Yao W; Lane NE; Harland RM; Loots GG
    Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14092-7. PubMed ID: 22886088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status.
    Ross RD; Mashiatulla M; Robling AG; Miller LM; Sumner DR
    Calcif Tissue Int; 2016 Feb; 98(2):149-57. PubMed ID: 26514840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC5 controls MEF2C-driven sclerostin expression in osteocytes.
    Wein MN; Spatz J; Nishimori S; Doench J; Root D; Babij P; Nagano K; Baron R; Brooks D; Bouxsein M; Pajevic PD; Kronenberg HM
    J Bone Miner Res; 2015 Mar; 30(3):400-11. PubMed ID: 25271055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
    Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
    J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes.
    Kim SP; Frey JL; Li Z; Kushwaha P; Zoch ML; Tomlinson RE; Da H; Aja S; Noh HL; Kim JK; Hussain MA; Thorek DLJ; Wolfgang MJ; Riddle RC
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11238-E11247. PubMed ID: 29229807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice.
    Robling AG; Kedlaya R; Ellis SN; Childress PJ; Bidwell JP; Bellido T; Turner CH
    Endocrinology; 2011 Aug; 152(8):2963-75. PubMed ID: 21652726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.